Abivax S.A.
NASDAQ:ABVXBiotechnology
-$0.62 today
- Market cap
- $7.34B
- Beta
- -0.20
- P/E (TTM)
- -18.1
- EPS (TTM)
- -$4.83
Volume 1.19M
Average 1.59M
ABVX Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Abivax S.A.NASDAQ: ABVX
Cash & Equivalents · Q2 FY2026 · quarter ended Jun 2026
Cash & equivalents rises 536.6% from a year ago
Cash & equivalents stood at €387.99M at the end of Q2 FY2026, up 536.6% from a year earlier. Over 3 fiscal years it compounded at +167.6% a year.
Context
- Cash & equivalents amounted to 83.9% of total assets at the end of Q2 FY2026, up 33.0 pp from a year earlier.
- Cash & equivalents increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +536.6% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
EUR · from the balance sheet
- Latest · FY2025
- 516.47M EUR
- Year-over-year change
- +258.1%
- 4-year CAGR
- +70.8%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 516.47M | +258.1% |
| FY2024 | 2024-12-31 | 144.22M | -42.8% |
| FY2023 | 2023-12-31 | 251.94M | +834.8% |
| FY2022 | 2022-12-31 | 26.95M | -55.6% |
| FY2021 | 2021-12-31 | 60.7M | — |
Cash & Equivalents vs competitors
How ABVX compares with its peers on the latest reported figures
- Peers report in different currencies, so cash & equivalents is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +536.6% is the 2nd highest of 11, against a peer median of +15.1%.
- Cash & equivalents amounts to 83.9% of total assets for ABVX, versus a peer median of 33.8%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Aug 2026 | $720.24M USD | +818.2% | +56.5% | 60.3% | |
| Jun 2026 | €387.99M EUR | +536.6% | +167.6% | 83.9% | |
| Mar 2026 | $248.47M USD | +151.9% | +49.5% | 75.4% | |
| Mar 2026 | $175.21M USD | +80.4% | +5.0% | 66.6% | |
| Jun 2026 | $150M USD | -39.5% | +2.5% | 16.2% | |
| Mar 2026 | $130.89M USD | -15.0% | +22.0% | 27.7% | |
| Dec 2025 | €99.27M EUR | +2.8% | +4.6% | 39.9% | |
| Sep 2026 | $82.73M USD | +27.5% | +35.0% | 7.5% | |
| Mar 2026 | $79.25M USD | +397.8% | +91.2% | 82.7% | |
| Mar 2026 | $28.66M USD | -5.6% | -23.9% | 14.4% | |
| Mar 2026 | $24.99M USD | -80.0% | +6.4% | 25.0% | |
| Peer median (excluding ABVX) | — | +15.1% | +14.2% | 33.8% | |
Competitors are the stored peer set for ABVX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 60.7M | 26.95M | 251.94M | 144.22M | 516.47M |
| Short-term Investments | 6K | 0 | 9.05M | 0 | 13.69M |
| Net Receivables | 8.34M | 8.32M | 19.1M | 15.66M | 10.49M |
| Inventory | 4M | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 0 | (1K) | 0 | 0 |
| Total Current Assets | 75.21M | 36.18M | 285.97M | 170.67M | 551.01M |
| Property, Plant & Equipment (Net) | 93K | 1.59M | 877K | 2.67M | 2.09M |
| Goodwill | 32.75M | 18.42M | 18.42M | 18.42M | 18.41M |
| Intangible Assets | (647K) | 6.61M | 6.6M | 6.61M | 6.6M |
| Long-term Investments | 214K | 0 | 124K | 126K | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 2.75M | 12.75M | 15.07M | 6.74M | 5.98M |
| Total Non-current Assets | 35.15M | 39.36M | 41.09M | 34.56M | 33.08M |
| Total Assets | 109.23M | 75.54M | 327.06M | 205.23M | 584.09M |
| Account Payables | 18.56M | 15.48M | 47.22M | 43.82M | 37.55M |
| Short-term Debt | 10.06M | 29.49M | 30.88M | 42.84M | 28.46M |
| Tax Payables | 88K | 86K | 2.38M | 4.71M | 0 |
| Deferred Revenue | 162K | 133K | 52K | 0 | 0 |
| Other Current Liabilities | (385K) | 2.87M | 3.51M | 532K | (15.91M) |
| Total Current Liabilities | 32.26M | 51.46M | 88.12M | 92.83M | 62.99M |
| Long-term Debt | 40.27M | 8.29M | 26.62M | 52.16M | 30.22M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 5.85M |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 10.37M | 7.77M | 16.15M | 18.22M | 29.46M |
| Total Non-current Liabilities | 51.03M | 16.89M | 42.94M | 71.81M | 66.09M |
| Total Liabilities | 83.3M | 68.36M | 131.05M | 164.64M | 129.08M |
| Common Stock | 168K | 223K | 629K | 633K | 784.67K |
| Retained Earnings | (81.81M) | (143.51M) | (282.95M) | (438.88M) | (738.17M) |
| Accumulated OCI | 1K | 302.03K | 112K | (75K) | 2.31M |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 25.93M | 7.19M | 196.01M | 40.58M | 455.01M |
| Total Debt | 51.65M | 39.16M | 58.04M | 97.36M | 45.89M |
| Net Debt | (9.05M) | 12.21M | (193.9M) | (46.86M) | (470.58M) |
Abivax S.A.
NASDAQ:ABVX
Intrinsic Alpha fair value
Locked
Current Price
$83.83
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.